Intravitreous ranibizumab as treatment for macular telangiectasia type 2.
Lira
Rodrigo Pessoa Cavalcanti
RP
State University of Campinas, Unicamp, Recife, Brazil. rodrigopclira@hotmail.com
Silva
Valdir Balarin
VB
Cavalcanti
Tiago Marques
TM
de Souza
Ana Catarina Delgado
AC
Pinto
Alexandre Paashaus da Costa
AP
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008875:Middle Aged; D000069579:Ranibizumab; D012160:Retina / Q000473:pathology; D012163:Retinal Detachment / Q000175:diagnosis / Q000503:physiopathology; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D013684:Telangiectasis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab